STAT+: Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest and more
Pharma news from the Pharmalot campus, brought to you by the Pharmalittle newsletter
AstraZeneca recently announced the disappointing failure of a significant heart disease clinical trial. The experimental drug, known as a silencer, failed to demonstrate any additional benefits for patients who were already taking stabilizer medications. This unexpected outcome marks a major setback for the multibillion dollar market, as reported by STAT.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
